Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Radiotherapy.
- Who it may be relevant to
- Registry conditions: Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Netherlands
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Motive: In order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients. Goal: To set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life. A standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.
Interventions
- Radiation Radiotherapy
Primary outcome measures
- Acute toxicity [Time frame: Highest during and within 2 weeks after last day of radiation therapy]
- Late toxicity [Time frame: Highest within one year after last day of radiation therapy]
Secondary outcome measures (8)
- Overall survival [Time frame: at 1 year after first day of radiation therapy]
- Overall survival [Time frame: at 2 years after first day of radiation therapy]
- Overall survival [Time frame: at 3 years after first day of radiation therapy]
- Overall survival [Time frame: at 4 years after first day of radiation therapy]
- Overall survival [Time frame: at 5 years after first day of radiation therapy]
- Loco-regional tumor control [Time frame: at 1 year after first day of radiation therapy]
- Loco-regional tumor control [Time frame: at 2 years after first day of radiation therapy]
- Loco-regional tumor control [Time frame: at 3 years after first day of radiation therapy]
Eligibility criteria
Inclusion criteria
- Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy)
- Patients receiving radiotherapy dose > 40 Gy
Exclusion criteria
- Failure to comply with any of the inclusion criteria
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Netherlands · 1 center
- University Medical Center Groningen — Groningen
Identifiers
NCT: NCT02421718 · SFP LUNG